Dihexa
Also known as: N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, N-hexanoic-tyrosine-isoleucine-(6) aminohexanoic amide, PNB-0408
Peptidomimetic / Angiotensin IV analog / HGF/c-Met receptor system activator
What it is
Dihexa is a synthetic compound studied in animals for its effects on memory, cognitive decline, and neurodegenerative diseases including Alzheimer's and Parkinson's. It is thought to work by activating pathways that support the growth of connections between neurons. Not FDA-approved; no human clinical trials completed; evidence is from animal models only.
The scientific side
Dihexa is a metabolically stabilized, orally bioavailable peptidomimetic derived from the N-terminal tripeptide (Nle-Tyr-Ile) of norleucine1-angiotensin IV, an analog of the endogenous hexapeptide angiotensin IV (AngIV: VYIHPF). Earlier AngIV analogs with procognitive properties were limited by rapid metabolic degradation and poor blood-brain barrier (BBB) permeability; Dihexa was chemically engineered to overcome both barriers, yielding an orally active compound that crosses the BBB (PMID 23055539, PMID 25455861). The primary mechanism is activation of the hepatocyte growth factor (HGF) / c-Met receptor system in the central nervous system. Dihexa binds with high affinity to HGF and potentiates its activation of the c-Met receptor. This HGF/c-Met signaling drives synaptogenesis, neurogenesis, and neuroprotection; synaptogenic effects were abolished by the selective c-Met inhibitor PHA-665752, confirming mechanism-dependence. Downstream, c-Met receptor activation stimulates mitogenesis, morphogenesis, stem cell differentiation, and neurogenesis across multiple cell types. In APP/PS1 Alzheimer's model mice, Dihexa additionally activates the PI3K/AKT signaling pathway. A 2018 systematic review of 32 animal studies confirmed that AngIV and its analogs — the class that includes Dihexa — produce consistent procognitive effects across rodent models of memory and learning, with efficacy seen in both normal animals and models of cognitive impairment. As of the reviewed literature, all mechanistic and efficacy data are preclinical; no human pharmacokinetic, pharmacodynamic, or efficacy data have been published.
Class: Peptidomimetic / Angiotensin IV analog / HGF/c-Met receptor system activator
Administration & storage
- Storage
- No storage data described in reviewed abstracts.
- Cautions
- No human safety data exists in reviewed literature; all safety assessment is from rodent studies only.,No adverse event data reported in reviewed animal study abstracts; absence of reported events in preclinical studies does not establish human safety.,Compound has not undergone Phase I human safety evaluation in any published study as of reviewed literature.
Legal & regulatory status
Not approved by the US FDA for any therapeutic indication. No completed human clinical trials reported in reviewed literature. Remains a preclinical research compound as of 2025.
Not stated in reviewed literature — requires manual verification. No evidence of inclusion on current prohibited list found in reviewed abstracts.
Not stated in reviewed literature — requires manual verification
What it's studied for
- Cognitive impairment and Alzheimer's disease model Animal studies only
- APP/PS1 Alzheimer's model mice treated with Dihexa at multiple oral doses showed restored spatial learning and cognitive function in the Morris water maze; Dihexa-treated animals had increased neuronal cell counts on Nissl staining, elevated SYP (synaptophysin) protein expression, and decreased amyloid-beta plaque load PMID 34827486 Sun X et al. Brain Sci. 2021.
- Dihexa and parent compound Nle1-AngIV demonstrated procognitive and synaptogenic effects in rodents. Dihexa bound hepatocyte growth factor (HGF) with high affinity and potentiated c-Met receptor activation; synaptogenic effects were completely blocked by the c-Met inhibitor PHA-665752, confirming HGF/c-Met pathway depe PMID 25187433 Benoist CC et al. J Pharmacol Exp Ther. 2014.
- Systematic review of 32 animal studies on AngIV and Ang-(1-7) cognitive effects. 7/11 normal-animal studies found AngIV beneficial on passive avoidance, conditioned avoidance, and object recognition tasks. 8/9 cognitive-impairment model studies found salutary effects of AngIV and its analogs (including Nle1-AngIV, the PMID 29733881 Ho JK et al. Neurosci Biobehav Rev. 2018.
- Parkinson's disease and neurodegenerative disease Animal studies only
- Review of the development of small-molecule AngIV analogs for Alzheimer's and Parkinson's disease. Documents the pharmacological rationale for Dihexa's design and summarizes preclinical evidence for AngIV analogs in dopaminergic and cholinergic models. Concludes that Dihexa and related analogs represent a novel drug de PMID 25455861 Wright JW et al. Prog Neurobiol. 2015.
- Huntington's disease model Animal studies only
- Dihexa (PNB-0408) administered to rats with 3-nitropropionic acid (3-NP)-induced Huntington's disease-like symptoms attenuated motor and cognitive impairment compared to vehicle controls. Authors cite Dihexa's prior success in Alzheimer's and Parkinson's animal models as the rationale. Specific dose, route, and sample PMID 38489193 Wells RG et al. J Huntington's Dis. 2024.
Safety signals
- No adverse events described in the APP/PS1 mouse study abstract at any tested dose of Dihexa. Absence of reported events in this single animal study does not establish safety in humans. PMID 34827486
- No human safety or tolerability data exists. No Phase I trial has been published in any reviewed abstract. All safety inference is from rodent models only. PMID 25455861
Contraindications
- No formal contraindications established in reviewed literature. Compound has not been evaluated in human clinical trials. Individuals on medications affecting the renin-angiotensin system (ACE inhibitors, ARBs) should consult a physician before use, given Dihexa's derivation from the angiotensin system. PMID 25649658
Protocol
1–5 mg Oral, Once daily. Cycle: 1–4 weeks.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Oral (capsule or liquid) | 1–5 mg | Once daily · 1–4 weeks on, then break | Nootropic users seeking cognitive enhancement, memory improvement | [Community] |
| Oral | 5–10 mg | Every other day · 2–4 weeks, then reassess | Older adults and biohackers using for age-related cognitive decline | [Community] |
| Sublingual | 1–3 mg | Once daily, morning · 2 weeks on, 2 weeks off | Nootropic stackers combining with other cognitive peptides | [Community] |
Blends containing this peptide
All studies (7)
- PMID 23055539
Not specified in abstract Not specified in abstract (animal) - PMID 25187433 Animal studies only
Cognitive impairment and Alzheimer's disease model - PMID 25455861 Animal studies only
Parkinson's disease and neurodegenerative disease - PMID 25649658
No formal contraindications established in reviewed literature. Compound has not been evaluated in human clinical trials. Individuals on medications affecting t - PMID 29733881 Animal studies only
Cognitive impairment and Alzheimer's disease model - PMID 34827486 Animal studies only
Cognitive impairment and Alzheimer's disease model - PMID 38489193 Animal studies only
Huntington's disease model